TMDX
$113.90+0.18 (+0.16%)
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a port...
Recent News
TransMedics Extends Decline as Selling Pressure Builds
Recent weakness continues despite supportive analyst view
Is TransMedics Group, Inc. (TMDX) A Good Stock To Buy Now?
Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on The Cash Flow Compounder’s Substack. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.’s share was trading at $129.61 as of March 6th. TMDX’s trailing and forward P/E were 26.61 and 56.18 respectively according to […]
Analysts Raise TransMedics Group, Inc. (TMDX) Price Targets After Q4 Results
TransMedics Group, Inc. (NASDAQ:TMDX) is one of the best under-the-radar stocks to buy according to hedge funds. On February 25, Baird raised its price target on TransMedics Group, Inc. (NASDAQ:TMDX) from $154 to $168 and kept its Outperform rating on the stock. Baird updated its model after the company reported fourth-quarter results that surpassed expectations […]
Assessing TransMedics Group (TMDX) Valuation After Recent Short Term Share Price Weakness
TransMedics Group (TMDX) has drawn investor attention after recent trading saw the stock close at US$129.61, with short term returns under pressure even as longer term performance and current fundamentals invite closer scrutiny. See our latest analysis for TransMedics Group. The recent 1 day share price decline of 7.47%, alongside a 7 day share price return of negative 10.77%, contrasts with a 1 year total shareholder return of 92.13%. This pattern suggests strong longer term momentum even as...
TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?
TransMedics continues to reinvent the organ transplant industry, but the market insists the stock is "overvalued" now.